Gilead's revenue rises 17% driven by sales of coronavirus treatment remdesivir

Remdesivir generated $873 million in sales during the third quarter, mostly in the U.S., the company said.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.